| Autor: |
Chatterjee, Krittika, Lakdawala, Sagheerah, Quadir, Sheikh Shahnawaz, Puri, Dinesh, Mishra, Dinesh Kumar, Joshi, Garima, Sharma, Sanjay, Choudhary, Deepak |
| Zdroj: |
AAPS PharmSciTech; Aug2023, Vol. 24 Issue 6, p1-24, 24p |
| Abstrakt: |
Since the ground-breaking discovery of RNA interference (RNAi), scientists have made significant progress in the field of small interfering RNA (siRNA) treatments. Due to severe barriers to the therapeutic application of siRNA, nanoparticle technologies for siRNA delivery have been designed. For pathological circumstances such as viral infection, toxic RNA abnormalities, malignancies, and hereditary diseases, siRNAs are potential therapeutic agents. However, systemic administration of siRNAs in vivo remains a substantial issue due to a lack of “drug-likeness” (siRNA are relatively larger than drugs and have low hydrophobicity), physiological obstacles, and possible toxicities. This write-up covers important accomplishment in the field of clinical trials and patents specially based of siRNAs using targeting viruses. Furthermore, it offers deep insight of nanoparticle applied for siRNA delivery and strategies to improve the effectiveness of antivirals. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink